Preston Noon

Dr. Preston Noon is Co-Founder and Partner at Agent Capital. Preston supports all Agent Capital fund activities, including leading new investments, portfolio management, and maintaining back-office functions. Prior to Agent Capital, Preston worked in the pharmaceutical industry for Bristol-Myers Squib, Bayer, and Baxalta (a NYSE-listed spinout from Baxter Healthcare). At Bayer, Preston was a post-doctoral Associate for the U.S. Business Development and Licensing group, where he worked on in-licensing assets, acquisitions and asset divestitures. Prior to Bayer, Preston was a global medical affairs analyst at Bristol-Myers Squibb. He began his career in the pharmaceutical industry working at Bristol-Myers Squibb to support clinical trial operations, specifically to monitor and improve enrollment timelines for next generation immuno-oncology assets including ipilimumab and nivolumab, which are now approved. Preston is a Kauffman Fellow, member of Class 23. He received a PharmD and MBA each from the University of Connecticut.